Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Injections Clear all
Completed Phase 2 Interventional

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00292396
View directory record Official record
Conditions
Psoriasis
Interventions
Anti IL-12 monoclonal antibody/ABT-874, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

NCT00115570
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin glulisine, insulin lispro, insulin glargine, NPH insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 17 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Long Term Open Label Continuation Study

NCT00195650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 22, 2026, 5:48 PM EDT
Withdrawn Phase 2 Interventional

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

NCT02269579
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

NCT02362646
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Ventricular Dysfunction
Interventions
MPC Intramyocardial Injection, Control Solution
Biological · Drug
Lead sponsor
Annetine Gelijns
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 22, 2026, 5:48 PM EDT
Completed No phase listed Observational

Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy

NCT01104142
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jul 22, 2026, 5:48 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

"Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome"

NCT03616262
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
Botox + Lidocaine, Lidocaine alone
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jul 22, 2026, 5:48 PM EDT
Completed No phase listed Observational

Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain

NCT01390103
View directory record Official record
Conditions
Hip Pain
Interventions
Assessment following hip injection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03006770
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
PLX-PAD, Placebo
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Jul 22, 2026, 5:48 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

NCT06817382
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
INS1201
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
2 Years to 4 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Little Rock, Arkansas • Davis, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA

NCT03608579
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Autologous Adipose Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

Injectable Filler for Cheek Flattening

NCT01225354
View directory record Official record
Conditions
Malar Deficiency
Interventions
Calcium hydroxylapatite
Drug
Lead sponsor
DeNova Research
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 22, 2026, 5:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Two Injection Locations in Obese Patients Having Lower Leg/Foot Surgery

NCT01550094
View directory record Official record
Conditions
Strain of Muscle and/or Tendon of Lower Leg, Fracture of Lower Leg, Crushing Injury of Lower Leg, Fracture Malunion - Ankle and/ or Foot, Complete Tear, Ankle and/or Foot Ligament, Pathological Fracture - Ankle and/or Foot, Loose Body in Joint of Ankle and/or Foot
Interventions
Not listed
Lead sponsor
Jose Soberon, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

NCT05158166
View directory record Official record
Conditions
Adductor Spasmodic Dysphonia, Voice Disorders, Spasmodic Dysphonia
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Intravenous (IV) Catheterization in Children

NCT00444756
View directory record Official record
Conditions
Pain
Interventions
J-tip jet injection of 1% buffered lidocaine
Procedure
Lead sponsor
Norton Healthcare
Other
Eligibility
8 Years to 15 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 7, 2007 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression

NCT00189605
View directory record Official record
Conditions
Radicular Pain
Interventions
Perc-DLR/Perc-DLG, Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
Device · Drug
Lead sponsor
ArthroCare Corporation
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
13
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Napa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 4 Interventional

Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment

NCT01722656
View directory record Official record
Conditions
Submacular Vascularized Pigment Epithelial Detachments
Interventions
Aflibercept
Drug
Lead sponsor
Southern California Desert Retina Consultants, MC
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Palm Desert, California • Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902
View directory record Official record
Conditions
Diabetic Retinopathy, HIV
Interventions
Tesamorelin, Placebo-Control
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Does Magnetic Resonance Imaging (MRI) Improve Interventional Outcomes for Lumbosacral Radiculopathy?

NCT00826124
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
Epidural steroid injection, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Jul 22, 2026, 5:48 PM EDT
Completed No phase listed Observational

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT04340505
View directory record Official record
Conditions
Uveitis
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1 Interventional Results available

Stem Cell Injection in Cancer Survivors

NCT02509156
View directory record Official record
Conditions
Cardiomyopathy Due to Anthracyclines
Interventions
Allo-MSCs, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 22, 2026, 5:48 PM EDT